Sanofi Total Common and Preferred Stock Dividends Paid 2010-2024 | SNY

Sanofi annual/quarterly total common and preferred stock dividends paid history and growth rate from 2010 to 2024. Total common and preferred stock dividends paid can be defined as the cash outflow for all company dividends paid out to preferred and common shareholders.
  • Sanofi total common and preferred stock dividends paid for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Sanofi total common and preferred stock dividends paid for the twelve months ending September 30, 2024 were $-9.986B, a 6.17% increase year-over-year.
  • Sanofi annual total common and preferred stock dividends paid for 2023 were $-4.887B, a 8.69% increase from 2022.
  • Sanofi annual total common and preferred stock dividends paid for 2022 were $-4.496B, a 6.31% decline from 2021.
  • Sanofi annual total common and preferred stock dividends paid for 2021 were $-4.799B, a 5.52% increase from 2020.
Sanofi Annual Total Common and Preferred Stock Dividends Paid
(Millions of US $)
2023 $-4,887
2022 $-4,496
2021 $-4,799
2020 $-4,547
2019 $-4,310
2018 $-4,472
2017 $-4,210
2016 $-4,183
2015 $-4,115
2014 $-4,900
2013 $-4,848
2012 $-4,497
2011 $-1,911
2010 $-4,158
2009 $-4,005
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $120.547B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $719.145B 74.49
Novo Nordisk (NVO) Denmark $464.190B 33.48
Johnson & Johnson (JNJ) United States $345.687B 14.02
AbbVie (ABBV) United States $303.100B 15.95
Merck (MRK) United States $251.749B 16.73
AstraZeneca (AZN) United Kingdom $199.805B 17.00
Novartis AG (NVS) Switzerland $197.798B 13.15
Pfizer (PFE) United States $146.038B 9.99
Innoviva (INVA) United States $1.122B 9.34